Early Access Program

Juno Diagnostics™ is a category-defining health company bringing vital prenatal health information to patients by combining accessibility, affordability, and transparency. The Company has developed a proprietary Sample Collection Kit and Device to facilitate capillary blood-based testing. Its lead product, the Juno Hazel™ screen, is a non-invasive prenatal screening (NIPS) test that utilizes the proprietary Sample Collection Kit and improves access to high-quality screening results without the high cost, long lead times, and phlebotomy requirements of venous-based NIPS.

Juno Hazel™ and Hazel™ Plus offer a comprehensive prenatal screening solution by screening for common chromosomal trisomies, sex chromosome aneuploidies, and fetal sex. The laboratory-developed test has been evaluated for clinical performance in multiple studies inclusive of >1,600 total venous and capillary samples.

Prenatal aneuploidy screening through Juno Hazel™ Plus offers an expected >99% sensitivity and >99.9% specificity for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome), and an expected >95% sensitivity for sex chromosome aneuploidies including Monosomy X (Turner syndrome), XXY syndrome (Klinefelter syndrome), Triple X syndrome, and XYY syndrome (Jacobs syndrome). 

*Our publication is submitted for peer review and available on a pre-print server.

Both the American College of Obstetricians & Gynecologists (ACOG) and the American College of Medical Genetics and Genomics (ACMG) agree that healthcare providers should counsel all patients - not just those with high-risk* pregnancies - about NIPS and other prenatal screening and diagnostic testing options.

However, many pregnant individuals do not have the opportunity to make an informed decision about the full spectrum of their prenatal screening and testing options.